Search

Your search keyword '"Lievens, Yolande"' showing total 33 results
Start Over Author "Lievens, Yolande" Database Supplemental Index
33 results on '"Lievens, Yolande"'

1. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results

Author

Levy, Antonin, Adebahr, Sonja, Hurkmans, Coen, Ahmed, Merina, Ahmad, Shahreen, Guckenberger, Matthias, Geets, Xavier, Lievens, Yolande, Lambrecht, Maarten, Pourel, Nicolas, Lewitzki, Victor, Konopa, Krzysztof, Franks, Kevin, Dziadziuszko, Rafal, McDonald, Fiona, Fortpied, Catherine, Clementel, Enrico, Fournier, Béatrice, Rizzo, Stefania, Fink, Christian, Riesterer, Oliver, Peulen, Heike, Andratschke, Nicolaus, McWilliam, Alan, Gkika, Eleni, Schimek-Jasch, Tanja, Grosu, Anca-Ligia, Le Pechoux, Cécile, Faivre-Finn, Corinne, and Nestle, Ursula

Abstract

The international phase II single-arm LungTech trial 22113-08113 of the European Organization for Research and Treatment of Cancer assessed the safety and efficacy of stereotactic body radiotherapy (SBRT) in patients with centrally located early-stage NSCLC.

Published
2024
Full Text
View/download PDF

2. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.

Author

Iyengar, Puneeth, All, Sean, Berry, Mark F., Boike, Thomas P., Bradfield, Lisa, Dingemans, Anne-Marie C., Feldman, Jill, Gomez, Daniel R., Hesketh, Paul J., Jabbour, Salma K., Jeter, Melenda, Josipovic, Mirjana, Lievens, Yolande, McDonald, Fiona, Perez, Bradford A., Ricardi, Umberto, Ruffini, Enrico, De Ruysscher, Dirk, Saeed, Hina, and Schneider, Bryan J.

Abstract

This joint guideline by American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) was initiated to review evidence and provide recommendations regarding the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC). Local therapy is defined as the comprehensive treatment of all known cancer—primary tumor, regional nodal metastases, and metastases—with definitive intent. ASTRO and ESTRO convened a task force to address 5 key questions focused on the use of local (radiation, surgery, other ablative methods) and systemic therapy in the management of oligometastatic NSCLC. The questions address clinical scenarios for using local therapy, sequencing and timing when integrating local with systemic therapies, radiation techniques critical for oligometastatic disease targeting and treatment delivery, and the role of local therapy for oligoprogression or recurrent disease. Recommendations were based on a systematic literature review and created using ASTRO guidelines methodology. Based on the lack of significant randomized phase 3 trials, a patient-centered, multidisciplinary approach was strongly recommended for all decision-making regarding potential treatment. Integration of definitive local therapy was only relevant if technically feasible and clinically safe to all disease sites, defined as 5 or fewer distinct sites. Conditional recommendations were given for definitive local therapies in synchronous, metachronous, oligopersistent, and oligoprogressive conditions for extracranial disease. Radiation and surgery were the only primary definitive local therapy modalities recommended for use in the management of patients with oligometastatic disease, with indications provided for choosing one over the other. Sequencing recommendations were provided for systemic and local therapy integration. Finally, multiple recommendations were provided for the optimal technical use of hypofractionated radiation or stereotactic body radiation therapy as definitive local therapy, including dose and fractionation. Presently, data regarding clinical benefits of local therapy on overall and other survival outcomes is still sparse for oligometastatic NSCLC. However, with rapidly evolving data being generated supporting local therapy in oligometastatic NSCLC, this guideline attempted to frame recommendations as a function of the quality of data available to make decisions in a multidisciplinary approach incorporating patient goals and tolerances. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial

Author

Spaas, Mathieu, Sundahl, Nora, Kruse, Vibeke, Rottey, Sylvie, De Maeseneer, Daan, Duprez, Fréderic, Lievens, Yolande, Surmont, Veerle, Brochez, Lieve, Reynders, Dries, Danckaert, Willeke, Goetghebeur, Els, Van den Begin, Robbe, Van Gestel, Dirk, Renard, Vincent, Dirix, Piet, and Ost, Piet

Abstract

IMPORTANCE: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs. OBJECTIVE: To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, or non–small cell lung carcinoma were eligible. A total of 99 patients were randomly assigned to either the control arm (n = 52) or the experimental arm (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental arm) withdrew consent and thus were not included in the analysis. Data analyses were performed between April 2022 and March 2023. INTERVENTIONS: Patients were randomized (1:1) to receive anti–PD-1/PD-1 ligand 1 ICIs alone as per standard of care (control arm) or combined with stereotactic body radiotherapy 3 × 8 gray to a maximum of 3 lesions prior to the second or third ICI cycle, depending on the frequency of administration (experimental arm). Randomization was stratified according to tumor histologic findings and disease burden (3 and fewer or more than 3 cancer lesions). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) as per immune Response Evaluation Criteria in Solid Tumors. Key secondary end points included overall survival (OS), objective response rate, local control rate, and toxic effects. Efficacy was assessed in the intention-to-treat population, while safety was evaluated in the as-treated population. RESULTS: Among 96 patients included in the analysis (mean age, 66 years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previous line of systemic treatment at time of inclusion. Seven patients allocated to the experimental arm did not complete the study-prescribed radiotherapy course due to early disease progression (n = 5) or intercurrent illness (n = 2). With a median (range) follow-up of 12.5 (0.7-46.2) months, median PFS was 2.8 months in the control arm compared with 4.4 months in the experimental arm (hazard ratio, 0.95; 95% CI, 0.58-1.53; P = .82). Between the control and experimental arms, no improvement in median OS was observed (11.0 vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48-1.41; P = .47), and objective response rate was not statistically significantly different (22% vs 27%; P = .56), despite a local control rate of 75% in irradiated patients. Acute treatment-related toxic effects of any grade and grade 3 or higher occurred in 79% and 18% of patients in the control arm vs 78% and 18% in the experimental arm, respectively. No grade 5 adverse events occurred. CONCLUSIONS AND RELEVANCE: This phase 2 randomized clinical trial demonstrated that while safe, adding subablative stereotactic radiotherapy of a limited number of metastatic lesions to ICI monotherapy failed to show improvement in PFS or OS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03511391

Published
2023
Full Text
View/download PDF

4. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer

Author

Asamura, Hisao, Nishimura, Katherine K., Giroux, Dorothy J., Chansky, Kari, Hoering, Antje, Rusch, Valerie, Rami-Porta, Ramón, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Araujo, Luiz Henrique, Beer, David, Bertoglio, Pietro, Beyruti, Ricardo, Billè, Andrea, Boubia, Souheil, Brambilla, Elisabeth, Cangir, A.K., Carbone, David, Cilento, Vanessa, Connolly, Casey, Darling, Gail, Detterbeck, Frank, Dibaba, Daniel, D’Journo, Xavier Benoit, Donington, Jessica, Eberhardt, Wilfried, Edwards, John, Erasmus, Jeremy, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Sallé, Françoise, Gautschi, Oliver, Gill, Ritu R., Giroux, Dorothy, Giuliani, Meredith, Goo, Jin Mo, Hasegawa, Seiki, Hirsch, Fred, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp, Kerr, Keith, Kim, Young Tae, Kim, Dong Kwan, Kindler, Hedy, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Mahar, Alyson, Marino, Mirella, Marom, Edith M., Matilla, José-María, van Meerbeeck, Jan, Montuenga, Luis M., Nicholson, Andrew, Nishimura, Katie, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Prosch, Helmut, Rice, David, Rimner, Andreas, Rosenthal, Adam, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Suárez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Watanabe, Shun-ichi, Wistuba, Ignacio, Wynes, Murry, and Yatabe, Yasushi

Abstract

In the past 20 years, the International Association for the Study of Lung Cancer (IASLC) has been working on a global project to revise the TNM classification of lung cancer. The first and second phases of the staging projects proposed recommendations for revision of the TNM classification, which were adopted by the Union for International Cancer Control and the American Joint Committee on Cancer as their seventh and eighth editions of the TNM classifications of lung cancer. For the third phase of the IASLC Staging Project, a new database of lung cancer cases diagnosed between January 2011 and December 2019 has been established. The Staging and Prognostic Factors Committee of the IASLC is in charge of the process of proposing new recommendations. The newly established database consisted of 124,581 cases. The data were obtained from Asia and Australia (56.0%), Europe (24.7%), North America (15.7%), South/Central America (3.4%), and Africa and the Middle East (0.1%). After cases with incomplete data are excluded, 87,043 cases were enrolled in the analysis, of which 52,069 (59.8%) were invasive adenocarcinoma and 15,872 (18.2%) were squamous cell carcinoma. Both clinical and pathologic stages were available in 44,831 (51.5%) cases. Analyses of this database are expected to provide proposals for changing the TNM classification toward the ninth edition, which is scheduled to be in use in January 2024. This newly established global database on lung cancer is described to provide fundamental elements for revisions of the TNM rules for staging lung cancer.

Published
2023
Full Text
View/download PDF

5. Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink.

Author

Borras, Josep M., Corral, Julieta, Aggarwal, Ajay, Audisio, Riccardo, Espinas, Josep Alfons, Figueras, Josep, Naredi, Peter, Panteli, Dimitra, Pourel, Nicolas, Prades, Joan, and Lievens, Yolande

Subjects
REIMBURSEMENT, ONCOLOGIC surgery, PAYMENT systems, ECONOMIC statistics, ONCOLOGISTS, GREY literature, TECHNICAL reports, ONCOLOGY nursing
Abstract

Complex surgery and radiotherapy are the central pillars of loco-regional oncology treatment. This paper describes the reimbursement schemes used in radiation and complex surgical oncology, reports on literature and policy reviews. A systematic review of the literature of the reimbursement models has been carried out separately for radiotherapy and complex cancer surgery based on PRISMA guidelines. Using searches of PubMed and grey literature, we identified articles from scientific journals and reports published since 2000 on provider payment or reimbursement systems currently used in radiation oncology and complex cancer surgery, also including policy models. Most European health systems reimburse radiotherapy using a budget-based, fee-for-service or fraction-based system; while few reimburse services according to an episode-based model. Also, the reimbursement models for cancer surgery are mostly restricted to differences embedded in the DRG system and adjustments applied to the fees, based on the complexity of each surgical procedure. There is an enormous variability in reimbursement across countries, resulting in different incentives and different amounts paid for the same therapeutic strategy. A reimbursement policy, based on the episode of care as the basic payment unit, is advocated for. Innovation should be tackled in a two-tier approach: one defining the common criteria for reimbursement of proven evidence-based interventions; another for financing emerging innovation with uncertain definitive value. Relevant clinical and economic data, also collected real-life, should support reimbursement systems that mirror the actual cost of evidence-based practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors

Author

Ruffini, Enrico, Rami-Porta, Ramon, Huang, James, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, Ayten Kayi, Cilento, Vanessa, Detterbeck, Frank, Falkson, Conrad, Fang, Wentao, Filosso, Pier Luigi, Giaccone, Giuseppe, Girard, Nicolas, Guerrera, Francesco, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew G., Okumura, Meinoshin, Rimner, Andreas, Simone, Charles B., Asamura, Hisao, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramon, Araujo, Luiz Henrique, Beer, David, Bertoglio, Pietro, Beyruti, Ricardo, Bille, Andrea, Boubia, Souheil, Brambilla, Elisabeth, Cangir, A.K., Cilento, Vanessa, Connolly, Casey, Darling, Gail, Detterbeck, Frank, Dibaba, Daniel, D’ Journo, Xavier Benoit, Eberhardt, Wilfried, Erasmus, Jeremy, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Salle, Françoise, Gill, Ritu R., Giroux, Dorothy, Giuliani, Meredith, Goo, Jin Mo, Hirsch, Fred, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp, Kerr, Keith, Kim, Young Tae, Kim, Dong Kwan, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Marino, Mirella, Marom, Edith M., Matilla, José-María, Meerbeeck, Jan van, Montuenga, Luis M., Nicholson, Andrew, Nishimura, Katie, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Rice, David, Rosenthal, Adam, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Suárez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Watanabe, Shun-Ichi, Wistuba, Ignacio, Wynes, Murry, Yatabe, Yasushi, Appel, Sarit, Armato, Samuel, Berzenji, Lawek, Brunelli, Alex, Cardillo, Giuseppe, Chen, Keneng, Cooper, Wendy, Filosso, Pier Luigi, Jiang, Liyan, Krasnik, Mark, Kubota, Kauro, Labbe, Catherine, Lee, Ho Yun, Lim, Eric, Liu, Geoffrey, Liu, Hongxu, Mack, Philip, Naidich, David, Nishino, Mizuki, Ostrowski, Marcin, Powell, Charles, Presley, Carolyn, Putora, Paul Martin, Ren, Harry, Rivera, M. Patricia, Rocco, Gaetano, Ruiz Tzukazan, Maria Teresa, Samstein, Robert, Soon, Yu Yang, Suda, Kenichi, Tammemägi, Martin, Turna, Akif, Weksler, Benny, Williams, Terence, Yang, Dawei, Yang, Jeff, Yotsukura, Masaya, Ahmad, Usman, Appel, Sarit, Brambilla, Cecilia, Falkson, Conrad B., Filosso, Pier Luigi, Giaccone, Giuseppe, Guerrera, Francesco, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Simone, Charles B., Ferguson, Mark, Sauter, Jennifer, Wolf, Andrea, Ruffini, Enrico, Huang, James, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, A.K., Detterbeck, Frank, Falkson, Conrad, Fang, Wentao, Filosso, Pier Liugi, Giaccone, Giuseppe, Girard, Nicolas, Guerrera, Francesco, Infante, Maurizio, Kim, Hong Kwan, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew, Okumura, Meinoshin, Rimner, Andreas, Simone, Charles B., Nicholson, Andrew, Brambilla, Cecilia, Cangir, A.K., Infante, Maurizio, Marino, Mirella, Marom, Edith M., Okumura, Meinoshin, Fang, Wentao, Detterbeck, Frank, Filosso, Pier Luigi, Lucchi, Marco, Marom, Edith M., Simone, Charles B., Girard, Nicolas, Appel, Sarit, Falkson, Conrad, Fang, Wentao, Giaccone, Giuseppe, Kim, Hong Kwuan, Rimner, Andreas, Filosso, Pier Luigi, Ahmad, Usman, Bille, Andrea, Boubia, Souheil, Detterbeck, Frank, Fang, Wentao, Girard, Nicolas, Guerrera, Francesco, Huang, James, Kim, Hong Kwan, Okumura, Meinoshin, and Ruffini, Enrico

Abstract

Thymic epithelial tumors are presently staged using a consistent TNM classification developed by the International Association for the Study of Lung Cancer (IASLC) and approved by the Union for International Cancer Control and the American Joint Committee on Cancer. The stage classification is incorporated in the eight edition of the TNM classification of thoracic malignancies. The IASLC Staging and Prognostic Factors Committee (SPFC)—Thymic Domain (TD) is in charge for the next (ninth) edition expected in 2024. The present article represents the midterm report of the SPFC-TD: in particular, it describes the unresolved issues identified by the group in the current stage classification which are worth being addressed and discussed for the ninth edition of the TNM classification on the basis of the available data collected in the central thymic database which will be managed and analyzed by Cancer Research And Biostatistics. These issues are grouped into issues of general importance and those specifically related to T, N, and M categories. Each issue is described in reference to the most recent reports on the subject, and the priority assigned by the IASLC SPFC-TD for the discussion of the ninth edition is provided.

Published
2022
Full Text
View/download PDF

7. Neurocognitive functioning following lung cancer treatment: The PRO-Long Study

Author

van der Weijst, Lotte, Lievens, Yolande, Surmont, Veerle, and Schrauwen, Wim

Abstract

•Lung cancer patients often receive loco-regional radiotherapy and systemic treatment.•This may negatively impact neurocognitive functioning (NCF) of certain patients.•Patient-reported psychological problems are not correlated with objective NCF.•Baseline objective NCF in lung cancer patients may be a predictor for overall survival.•More research is needed on the impact of systemic treatment and/or radiotherapy on cognition.

Published
2022
Full Text
View/download PDF

8. Incidence and radiotherapy treatment patterns of complicated bone metastases.

Author

Peters, Cedric, Vandewiele, Julie, Lievens, Yolande, van Eijkeren, Marc, Fonteyne, Valérie, Boterberg, Tom, Deseyne, Pieter, Veldeman, Liv, De Neve, Wilfried, Monten, Chris, Braems, Sabine, Duprez, Fréderic, Vandecasteele, Katrien, and Ost, Piet

Abstract

• Approximately 37% of bone metastases are classified as complicated. • The vast majority are of spinal origin. • The majority of complications were related to impending fracture. • Patients with complicated bone metastases have a median survival of 4 months. Despite the encouraging results of the SCORAD trial, single fraction radiotherapy (SFRT) remains underused for patients with complicated bone metastases with rates as low as 18–39%. We aimed to evaluate the incidence and treatment patterns of these metastases in patients being referred to a tertiary centre for palliative radiotherapy. We performed a retrospective review of all bone metastases treated at our centre from January 2013 until December 2017. Lesions were classified as uncomplicated or complicated. Complicated was defined as associated with (impending) fracture, existing spinal cord or cauda equina compression. Our protocol suggests using SFRT for all patients with complicated bone metastases, except for those with symptomatic neuraxial compression and a life expectancy of ≥28 weeks. Overall, 37 % of all bone metastases were classified as complicated. Most often as a result of an (impending) fracture (56 %) or spinal cord compression (44 %). In 93 % of cases, complicated lesions were located in the spine, most commonly originating from prostate, breast and lung cancer (60 %). Median survival of patients with complicated bone metastases was 4 months. The use of SFRT for complicated bone metastases increased from 51 % to 85 % over the study period, reaching 100 % for patients with the poorest prognosis. Approximately 37 % of bone metastases are classified as complicated with the majority related to (impending) fracture. Patients with complicated bone metastases have a median survival of 4 months and were mostly treated with SFRT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer

Author

Edwards, John G., Chansky, Kari, Van Schil, Paul, Nicholson, Andrew G., Boubia, Souheil, Brambilla, Elisabeth, Donington, Jessica, Galateau-Sallé, Françoise, Hoffmann, Hans, Infante, Maurizio, Marino, Mirella, Marom, Edith M., Nakajima, Jun, Ostrowski, Marcin, Travis, William D., Tsao, Ming-Sound, Yatabe, Yasushi, Giroux, Dorothy J., Shemanski, Lynn, Crowley, John, Krasnik, Marc, Asamura, Hisao, Rami-Porta, Ramón, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Araujo, Luiz Henrique, Beer, David, Bertoglio, Pietro, Beyruti, Ricardo, Bille, Andrea, Bolejack, Vanessa, Boubia, Souheil, Brambilla, Elisabeth, Brierley, James D., Cangir, A.K., Carbone, David, Chansky, Kari, Crowley, John, Darling, Gail, Detterbeck, Frank, D’Journo, Xavier Benoit, Donnington, Jessica, Eberhardt, Wilfried, Edwards, John, Erasmus, Jeremy, Falkson, Conrad, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Salle, Françoise, Gautschi, Oliver, Gill, Ritu, Giroux, Dorothy, Giuliani, Meredith, Goo, Jin Mo, Hasegawa, Seiki, Hirsch, Fred, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp, Kerr, Keith, Kim, Young Tae, Kim, Hong Kwan, Kindler, Hedy, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Marino, Mirella, Marom, Edith, Matilla, José-María, van Meerbeeck, Jan, Montuenga, Luis M., Nicholson, Andrew, Nishimura, Katie, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Prosch, Helmut, Rice, David, Rimner, Andreas, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Stoll-D’Astice, Amy, Su´rez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Waller, David, Watanabe, Shun-ichi, Wiens, Jacinta, Wistuba, Ignacio, Yatabe, Yasushi, Jiang, Liyan, Kubota, Kaoru, Turna, Akif, Weksler, Benny, Tzukazan, Maria Teresa, Tammemägi, Martin, Powell, Charles, Naidich, David, Liu, Hongxu, Turna, Akif, Armato, Samuel, Brunelli, Alex, Cardillo, Giuseppe, David, Elizabeth, Fournier, Brigitte, Krasnik, Mark, Kubota, Kauro, Labbe, Catherine, Lim, Eric, Putora, Paul Martin, Rocco, Gaetano, Filosso, Pier Luigi, Filosso, Pier Luigi, Kondo, Kazuya, Kim, Dong Kwan, Giaccone, Giuseppe, Lucchi, Marco, Infante, Maurizio, Rice, Thomas, Ferguson, Mark, Adsusmilli, Prasad, Asamura, Hisao, Van Schil, Paul, Kernstine, Kemp, Asamura, Hisao, Cangir, A.K., Liu, Hui, Lievens, Yolande, Donnington, Jessica, Fang, Wentao, Lyons, Gustavo, Travis, William, Kim, Young Tae, Sakai, Shuji, Ugalde, Paula, Bertoglio, Pietro, Huang, James, Kernstine, Kemp, Osarogiagbon, Raymond U., Suárez, Francisco, Rusch, Valerie, Rice, David, Beyruti, Ricardo, Kim, Hong Kwan, Van Schil, Paul, Watanabe, Shun-ichi, Prosch, Helmut, Marom, Edith, Putora, Paul Martin, Lievens, Yolande, Bille, Andrea, Cardillo, Giuseppe, Kubota, Kaura, Lim, Eric, Rocco, Gaetano, Fong, Kwun, Singh, Navneet, Eberhardt, Wilfried, Lievens, Yolande, Marino, Mirella, Erasmus, Jeremy, Putora, Paul Martin, Marom, Edith, Suárez, Francisco, Travis, William, Shun-ichi, Hisao Asamura, Watanabe, Sakai, Shuji, Yatabe, Yasushi, Prosch, Helmut, Hoffman, Hans, Edwards, John, Joubert, Philippe, Gill, Ritu, Goo, Jin Mo, Nicholson, Andrew G., Kim, Young Tae, MacMahon, Heber, Detterbeck, Frank, Ramón, Edith Marom, Rami-Porta, Rusch, Valerie, Cardillo, Giuseppe, Naidich, David, Tsao, Ming, Nicholson, Andrew G., Eberhardt, Wilfried, Beyruti, Ricardo, Yatabe, Yasushi, Travis, William, Matilla, José-María, Lievens, Yolande, Detterbeck, Frank, Lim, Eric, Filosso, Pier Luigi, Asamura, Hisao, Rami-Porta, Ramón, Huang, James, Fong, Kwun, Travis, William, Shun-ichi, Ming Tsao, Watanabe, Nicholson, Andrew G., Detterbeck, Frank, Edwards, John, Guiliani, Meredith, Van Schil, Paul, Kernstine, Kemp, Marom, Edith, Cardillo, Giuseppe, David, Elizabeth, Watanabe, Shun-ichi, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Hoffman, Hans, Van Schil, Paul, Kernstine, Kemp, Osarogiagbon, Raymond U., Goo, Jin Mo, Detterbeck, Frank, Brierley, James, Osarogiagbon, Raymond U., Marino, Mirella, Asamura, Hisao, Rusch, Valerie, Detterbeck, Frank, Nicholson, Andrew G., Fong, Kwun, Kim, Young Tae, Huang, James, van Meerbeeck, Jan, Tsao, Ming, Turna, Akif, Singh, Navneet, Terra, Ricardo, Osarogiagbon, Ray, Montuenga, Luis, Brierley, James, Rusch, Valerie, Wang, Hongwei, Nishimura, Katie, Tammemägi, Martin, Krasnik, Mark, Brunelli, Alex, Edwards, John, Hoffman, Hans, Boubia, Souheil, Nakajima, Jun, Van Schil, Paul, Donnington, Jessica, Brambilla, Elisabeth, Marom, Edith, Nicholson, Andrew G., Marino, Mirella, Galateau, Françoise, Travis, William, Yatabe, Yasushi, Tsao, Ming, Infante, Maurizio, Ostrowski, Marcin, MacMahon, Heber, Marom, Edith, Goo, Jim Mo, Gill, Ritu, Van Schil, Paul, Travis, Bill, Powell, Charles, Armato, Samuel, Naidich, David, Detterbeck, Frank, Marom, Edith, Nicholson, Andrew G., Travis, William, Ugalde, Paula, Terra, Ricardo M., Lim, Eric, Carbone, David, Hirsch, Fred, Wistuba, Ignacio, Kerr, Keith, Brambilla, Elisabeth, Gautschi, Oliver, Yatabe, Yasushi, Araujo, Luiz Henrique, Pass, Harvey, Tsao, Ming, Rami-Porta, Ramón, Travis, William, Detterbeck, Frank, Nicholson, Andrew G., Asamura, Hisao, Montuenga, Luis, Terra, Ricardo M., Osarogiagbon, Raymond U., Matilla, José-María, Fennell, Dean, Beer, David, Ugalde, Paula, Joubert, Philippe, Lyons, Gustavo, Terra, Ricardo, Bertoglio, Pietro, Matilla, Jose Maria, Labbe, Catherine, Fournier, Brigitte, St. Pierre, Carolle, Weksler, Benny, Liu, Hongxu, Tzukazan, Ma Teresa, Ruffini, Enrico, Huang, James, Fang, Wentao, Detterbeck, Frank, Marom, Edith, Marino, Mirella, Boubia, Souheil, Cangir, A.K., Bille, Andrea, Rimner, Andreas, Okumura, Meinoshin, Nicholson, Andrew, Girard, Nicholas, Infante, Maurizio, Giaccone, Giuseppe, Filosso, Pier Luigi, Kondo, Kazuya, Lucchi, Marco, Falkson, Conrad, Kim, Dong Kwan, Rusch, Valerie, Nowak, Anna, Opitz, Isabelle, Bille, Andrea, de Perrot, Marc, Rimmer, Andreas, Gill, Ritu, Kim, Hong Kwan, Rice, David, Kindler, Hedy, Fennell, Dean, van Meerbeeck, Jan, Galateau, Francoise, Hasegawa, Seiki, Bertoglio, Pietro, Tsao, Ming, Pass, Harvey, Adusumilli, Prasad, Darling, Gail, D’Journo, Xavier, Low, Donald, Hofstetter, Wayne, Kim, Hong Kwan, Fang, Wentao, Erasmus, Jeremy, Ugalde, Paula, Ferguson, Mark, Crowley, John, Chansky, Kari, Giroux, Dorothy, Bolejack, Vanessa, Stoll-D’Astice, Amy, Nishimura, Katie, and Rosenthal, Adam

Abstract

Our aim was to validate the prognostic relevance in NSCLC of potential residual tumor (R) descriptors, including the proposed International Association for the Study of Lung Cancer definition for uncertain resection, referred to as R(un).

Published
2020
Full Text
View/download PDF

10. Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?

Author

Belderbos, José S.A., De Ruysscher, Dirk K.M., De Jaeger, Katrien, Koppe, Friederike, Lambrecht, Maarten L.F., Lievens, Yolande, Dieleman, Edith M.T., Jaspers, Jaap P.M., Van Meerbeeck, Jan P., Ubbels, Fred, Kwint, Magriet, Kuenen, Marianne, Deprez, Sabine, De Ruiter, Michiel B., Boogerd, Willem, Sikorska, Karolina, Van Tinteren, Harm, and Schagen, Sanne B.

Published
2021
Full Text
View/download PDF

11. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC

Author

Travis, William D., Eisele, Megan, Nishimura, Katherine K., Aly, Rania, Bertoglio, Pietro, Chou, Teh-Ying, Detterbeck, Frank C., Donnington, Jessica, Fang, Wentao, Joubert, Philippe, Kernstine, Kemp, Kim, Young Tae, Lievens, Yolande, Liu, Hui, Lyons, Gustavo, Mino-Kenudson, Mari, Nicholson, Andrew G., Papotti, Mauro, Rami-Porta, Ramon, Rusch, Valerie, Sakai, Shuji, Ugalde, Paula, Van Schil, Paul, Yang, Jeff, Cilento, Vanessa J., Yotsukura, Masaya, and Asamura, Hisao

Abstract

Spread through air spaces (STAS) consists of lung cancer tumor cells that are identified beyond the edge of the main tumor in the surrounding alveolar parenchyma. It has been reported by meta-analyses to be an independent prognostic factor in the major histologic types of lung cancer, but its role in lung cancer staging is not established. To assess the clinical importance of STAS in lung cancer staging, we evaluated 4061 surgically resected pathologic stage I R0 NSCLC collected from around the world in the International Association for the Study of Lung Cancer database. We focused on whether STAS could be a useful additional histologic descriptor to supplement the existing ones of visceral pleural invasion (VPI) and lymphovascular invasion (LVI). STAS was found in 930 of 4061 of the pathologic stage I NSCLC (22.9%). Patients with tumors exhibiting STAS had a significantly worse recurrence-free and overall survival in both univariate and multivariable analyses involving cohorts consisting of all NSCLC, specific histologic types (adenocarcinoma and other NSCLC), and extent of resection (lobar and sublobar). Interestingly, STAS was independent of VPI in all of these analyses. These data support our recommendation to include STAS as a histologic descriptor for the Ninth Edition of the TNM Classification of Lung Cancer. Hopefully, gathering these data in the coming years will facilitate a thorough analysis to better understand the relative impact of STAS, LVI, and VPI on lung cancer staging for the Tenth Edition TNM Stage Classification.

Published
2024
Full Text
View/download PDF

12. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer

Author

Fong, Kwun M., Rosenthal, Adam, Giroux, Dorothy J., Nishimura, Katherine K., Erasmus, Jeremy, Lievens, Yolande, Marino, Mirella, Marom, Edith M., Putora, Paul Martin, Singh, Navneet, Suárez, Francisco, Rami-Porta, Ramon, Detterbeck, Frank, Eberhardt, Wilfried EE., and Asamura, Hisao

Abstract

This study analyzed all metastatic categories of the current tumor, node, and metastasis (TNM) classification of non-small cell lung cancer to propose modifications of the M component in the next edition (9th) of the classification.

Published
2024
Full Text
View/download PDF

13. The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9th) Edition of the TNM Classification of Lung Cancer

Author

Detterbeck, Frank C., Ostrowski, Marcin, Hoffmann, Hans, Rami-Porta, Ramón, Osarogiagbon, Ray U., Donnington, Jessica, Infante, Maurizio, Marino, Mirella, Marom, Edith M., Nakajima, Jun, Nicholson, Andrew G., van Schil, Paul, Travis, William D., Tsao, Ming S., Edwards, John G., Asamura, Hisao, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Araujo, Luiz Henrique, de Janeiro, Rio, Beer, David, Arbor, Ann, Bertoglio, Pietro, Beyruti, Ricardo, Bille, Andrea, Boubia, Souheil, Brambilla, Elisabeth, Cangir, A.K., Carbone, David, Cilento, Vanessa, Connolly, Casey, Darling, Gail, Detterbeck, Frank, Dibaba, Daniel, D’Journo, Xavier Benoit, Donington, Jessica, Eberhardt, Wilfried, Edwards, John, Eisele, Megan, Erasmus, Jeremy, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Salle, Françoise, Gill, Ritu R., Giroux, Dorothy, Giuliani, Meredith, Goo, Jin Mo, Hasegawa, Seiki, Goren, Emily, Hirsch, Fred, Hoering, Antje, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp H., Kerr, Keith, Kim, Young Tae, Kim, Hong Kwan, Kindler, Hedy, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Mahar, Alyson, Marino, Mirella, Marom, Edith M., Matilla, José-María, van Meerbeeck, Jan, Montuenga, Luis M., Nicholson, Andrew G., Nishimura, Katie, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Prosch, Helmut, Rice, David, Rimner, Andreas, Rosenthal, Adam, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Suárez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Watanabe, Shun-ichi, Wistuba, Ignacio, Wynes, Murry, Yatabe, Yasushi, Armato, Samuel, Berzenji, Lawek, Brunelli, Alex, Cardillo, Giuseppe, Chang, Jason, Chen, Keneng, Cooper, Wendy, Filosso, Pier Luigi, Jiang, Liyan, Karim, Nagla, Kneuertz, Peter, Krasnik, Mark, Labbe, Catherine, Lee, Ho Yun, Lim, Eric, Liu, Geoffrey, Liu, Hongxu, Mack, Philip, Naidich, David, Nishino, Mizuki, Ostrowski, Marcin, Powell, Charles, Presley, Carolyn, Putora, Paul Martin, Rekhtman, Natasha, Ren, Harry, Rivera, M Patricia, Hill, Chapel, Rocco, Gaetano, Ruiz Tzukazan, Maria Teresa, Soon, Yu Yang, Suda, Kenichi, Tammemägi, Martin, Tanoue, Lynn, Turna, Akif, Weksler, Benny, Williams, Terence, Yang, Dawei, Yang, Jeff, Yotsukura, Masaya, Ahmad, Usman, Appel, Sarit, Brambilla, Cecilia, Falkson, Conrad B., Filosso, Pier Luigi, Giaccone, Giuseppe, Guerrera, Francesco, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Roden, Anja, Simone, Charles B., Ferguson, Mark, Sauter, Jennifer, and Wolf, Andrea

Abstract

The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind. For lung cancer, an additional category encompasses situations in which the presence of residual tumor is uncertain. This paper represents a comprehensive review of evidence regarding these R categories and the descriptors thereof, focusing on studies published after the year 2000 and with adjustment for potential confounders. Consistent discrimination between complete, uncertain, and incomplete resection is demonstrated with respect to overall survival. Evidence regarding specific descriptors is generally somewhat limited and only partially consistent; nevertheless, the data suggests retaining all descriptors but with clarifications to address ambiguities. Based on this review, the R-classification for the 9thedition of stage classification of lung cancer is proposed to retain the same overall framework and descriptors, with more precise definitions of descriptors. These refinements should facilitate application as well as further research.

Published
2024
Full Text
View/download PDF

14. Provision and use of radiotherapy in Europe.

Author

Lievens, Yolande, Borras, Josep M., and Grau, Cai

Abstract

Radiation therapy is one of the core components of multidisciplinary cancer care. Although ~ 50% of all European cancer patients have an indication for radiotherapy at least once in the course of their disease, more than one out of four cancer patients in Europe do not receive the radiotherapy they need. There are multiple reasons for this underutilisation, with limited availability of the necessary resources – in terms of both trained personnel and equipment – being a major underlying cause of suboptimal access to radiotherapy. Moreover, large variations across European countries are observed, not only in available radiotherapy equipment and personnel per inhabitant or per cancer patient requiring radiotherapy, but also in workload. This variation is in part determined by the country's gross national income. Radiation therapy and technology are advancing quickly; hence, recommendations supporting resource planning and investment should reflect this dynamic environment and account for evolving treatment complexity and fractionation schedules. The forecasted increase in cancer incidence, the rapid introduction of innovative cancer treatments and the more active involvement of patients in the healthcare discussion are all factors that should be taken under consideration. In this continuously changing oncology landscape, reliable data on the actual provision and use of radiotherapy, the optimal evidence‐based demand and the future needs are crucial to inform cancer care planning and address and overcome the current inequalities in access to radiotherapy in Europe. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

15. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Author

Dingemans, Anne-Marie C., Hendriks, Lizza E.L., Berghmans, Thierry, Levy, Antonin, Hasan, Baktiar, Faivre-Finn, Corinne, Giaj-Levra, Matteo, Giaj-Levra, Niccolò, Girard, Nicolas, Greillier, Laurent, Lantuéjoul, Sylvie, Edwards, John, O’Brien, Mary, Reck, Martin, Smit, Egbert F., Van Schil, Paul, Postmus, Pieter E., Ramella, Sara, Lievens, Yolande, Gaga, Mina, Peled, Nir, Scagliotti, Giorgio V., Senan, Suresh, Paz-Ares, Luiz, Guckenberger, Matthias, McDonald, Fiona, Ekman, Simon, Cufer, Tanja, Gietema, Hester, Infante, Maurizio, Dziadziuszko, Rafal, Peters, Solange, Porta, Ramon Rami, Vansteenkiste, Johan, Dooms, Christophe, de Ruysscher, Dirk, Besse, Benjamin, and Novello, Silvia

Abstract

Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process.

Published
2019
Full Text
View/download PDF

16. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation

Author

Giroux, Dorothy J., Van Schil, Paul, Asamura, Hisao, Rami-Porta, Ramón, Chansky, Kari, Crowley, John J., Rusch, Valerie W., Kernstine, Kemp, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Araujo, Luiz Henrique, Beckett, Paul, Beer, David, Bertoglio, Pietro, Beyruti, Ricardo, Bille, Andrea, Bolejack, Vanessa, Boubia, Souheil, Brambilla, Elisabeth, Brierley, James D., Cangir, A.K., Carbone, David, Chansky, Kari, Crowley, John, Darling, Gail, Detterbeck, Frank, D’Journo, Xavier Benoit, Donnington, Jessica, Eberhardt, Wilfried, Edwards, John, Erasmus, Jeremy, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Salle, Françoise, Gautschi, Oliver, Gill, Ritu, Giroux, Dorothy, Goo, Jin Mo, Hasegawa, Seiki, Hirsch, Fred, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp, Kerr, Keith, Kim, Young Tae, Kim, Hong Kwan, Kindler, Hedy, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Marino, Mirella, Marom, Edith, Matilla, José-María, van Meerbeeck, Jan, Montuenga, Luis M., Nicholson, Andrew, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Prosch, Helmut, Rice, David, Rimner, Andreas, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Stoll-D’Astice, Amy, Suárez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Watanabe, Shun-ichi, Wiens, Jacinta, Wistuba, Ignacio, Yatabe, Yasushi, Jiang, Liyan, Kubota, Kaoru, Lim, Eric, Putora, Paul Martin, Turna, Akif, Filosso, Pier Luigi, Kondo, Kazuya, Kim, Dong Kwan, Giaccone, Giuseppe, Lucchi, Marco, Blackwell, Eugene, Rice, Thomas, Asamura, Hisao, Van Schil, Paul, Kernstine, Kemp, Asamura, Hisao, Cangir, A.K., Liu, Hui, Donnington, Jessica, Fang, Wentao, Lyons, Gustavo, Travis, William, Kim, Young Tae, Sakai, Shuji, Ugalde, Paula, Bertoglio, Pietro, Huang, James, Kernstine, Kemp, Osarogiagbon, Raymond U., Suárez, Francisco, Rusch, Valerie, Rice, David, Beyruti, Ricardo, Kim, Hong Kwan, Van Schil, Paul, Watanabe, Shun-ichi, Prosch, Helmut, Marom, Edith, Fong, Kwun, Singh, Navneet, Fennell, Dean, Eberhardt, Wilfried, Lievens, Yolande, Marino, Mirella, Erasmus, Jeremy, Putora, Paul Martin, Marom, Edith, Suárez, Francisco, Travis, William, Asamura, Hisao, Watanabe, Shun-ichi, Sakai, Shuji, Yatabe, Yasushi, Prosch, Helmut, Hoffman, Hans, Edwards, John, Joubert, Philippe, Gill, Ritu, Goo, Jin Mo, Nicholson, Andrew G., Kim, Young Tae, MacMahon, Heber, Detterbeck, Frank, Marom, Edith, Tsao, Ming, Nicholson, Andrew G., Eberhardt, Wilfried, Beyruti, Ricardo, Yatabe, Yasushi, Travis, William, Matilla, José-María, Lievens, Yolande, Detterbeck, Frank, Lim, Eric, Asamura, Hisao, Rami-Porta, Ramón, Huang, James, Fong, Kwun, Travis, William, Tsao, Ming, Watanabe, Shun-ichi, Nicholson, Andrew G., Detterbeck, Frank, Edwards, John, Brierley, James, Van Schil, Paul, Kernstine, Kemp, Marom, Edith, Watanabe, Shun-ichi, Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Hoffman, Hans, Van Schil, Paul, Kernstine, Kemp, Osarogiagbon, Raymond U., Goo, Jin Mo, Marom, Edith, Detterbeck, Frank, Brierley, James, Osarogiagbon, Raymond U., Beckett, Paul, Marino, Mirella, Asamura, Hisao, Rusch, Valerie, Lim, Eric, Detterbeck, Frank, Nicholson, Andrew G., Fong, Kwun, Kim, Young Tae, Huang, James, van Meerbeeck, Jan, Tsao, Ming, Edwards, John, Hoffman, Hans, Boubia, Souheil, Nakajima, Jun, Van Schil, Paul, Donnington, Jessica, Brambilla, Elisabeth, Marom, Edith, Nicholson, Andrew G., Marino, Mirella, Galateau, Françoise, Travis, Bill, Yatabe, Yasushi, Tsao, Ming, MacMahon, Heber, Marom, Edith, Goo, Jim Mo, Gill, Ritu, Detterbeck, Frank, Marom, Edith, Nicholson, Andrew G., Travis, William, Ugalde, Paula, Terra, Ricardo M., Lim, Eric, Carbone, David, Hirsch, Fred, Wistuba, Ignacio, Kerr, Keith, Brambilla, Elisabeth, Gautschi, Oliver, Yatabe, Yasushi, Araujo, Luiz Henrique, Pass, Harvey, Tsao, Ming, Rami-Porta, Ramón, Travis, William, Detterbeck, Frank, Nicholson, Andrew G., Asamura, Hisao, Joubert, Philippe, Montuenga, Luis, Terra, Ricardo M., Osarogiagbon, Raymond U., Matilla, José-María, Fennell, Dean, Beer, David, Wiens, Jacinta, Lim, Eric, Crowley, John, Chansky, Kari, Giroux, Dorothy, Bolejack, Vanessa, Stoll-D’Astice, Amy, Wang, Hong Wei, and Nishimura, Katie

Abstract

Over the past two decades, the International Association for the Study of Lung Cancer (IASLC) Staging Project has been a steady source of evidence-based recommendations for the TNM classification for lung cancer published by the Union for International Cancer Control and the American Joint Committee on Cancer. The Staging and Prognostic Factors Committee of the IASLC is now issuing a call for participation in the next phase of the project, which is designed to inform the ninth edition of the TNM classification for lung cancer. Following the case recruitment model for the eighth edition database, volunteer site participants are asked to submit data on patients whose lung cancer was diagnosed between January 1, 2011, and December 31, 2019, to the project by means of a secure, electronic data capture system provided by Cancer Research And Biostatistics in Seattle, Washington. Alternatively, participants may transfer existing data sets. The continued success of the IASLC Staging Project in achieving its objectives will depend on the extent of international participation, the degree to which cases are entered directly into the electronic data capture system, and how closely externally submitted cases conform to the data elements for the project.

Published
2018
Full Text
View/download PDF

17. Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675)

Author

Belderbos, José S.A., De Ruysscher, Dirk K.M., De Jaeger, Katrien, Koppe, Friederike, Lambrecht, Maarten L.F., Lievens, Yolande N., Dieleman, Edith M.T., Jaspers, Jaap P.M., Van Meerbeeck, Jan P., Ubbels, Fred, Kwint, Margriet H., Kuenen, Marianne A., Deprez, Sabine, De Ruiter, Michiel B., Boogerd, Willem, Sikorska, Karolina, Van Tinteren, Harm, and Schagen, Sanne B.

Published
2021
Full Text
View/download PDF

19. Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium

Author

Fonteyne, Valérie, Rammant, Elke, Ost, Piet, Lievens, Yolande, De Troyer, Bart, Rottey, Sylvie, De Meerleer, Gert, De Maeseneer, Daan, De Ridder, Dirk, and Decaestecker, Karel

Abstract

There is a gap between optimal and actual use of radiotherapy (RT) in muscle-invasive bladder cancer (MIBC). We investigated the opinions of radiation-oncologists, urologists, and medical oncologists on use of RT in different cases. Barriers and facilitators for applying guidelines were examined.

Published
2018
Full Text
View/download PDF

20. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer

Author

Osarogiagbon, Raymond Uyiosa, Van Schil, Paul, Giroux, Dorothy J., Lim, Eric, Putora, Paul Martin, Lievens, Yolande, Cardillo, Giuseppe, Kim, Hong Kwan, Rocco, Gaetano, Bille, Andrea, Prosch, Helmut, Vásquez, Francisco Suárez, Nishimura, Katherine K., Detterbeck, Frank, Rami-Porta, Ramon, Rusch, Valerie W., Asamura, Hisao, and Huang, James

Abstract

The status of lymph node involvement is a major component of the TNM staging system. The N categories for lung cancer have remained unchanged since the fourth edition of the TNM staging system, partly because of differences in nodal mapping nomenclature, partly because of insufficient details to verify possible alternative approaches for staging. In preparation for the rigorous analysis of the International Association for the Study of Lung Cancer database necessary for the ninth edition TNM staging system, members of the N-Descriptors Subcommittee of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee reviewed the evidence for alternative approaches to categorizing the extent of lymph node involvement with lung cancer, which is currently based solely on the anatomical location of lymph node metastasis. We reviewed the literature focusing on NSCLC to stimulate dialogue and mutual understanding among subcommittee members engaged in developing the ninth edition TNM staging system for lung cancer, which has been proposed for adoption by the American Joint Committee on Cancer and Union for International Cancer Control in 2024. The discussion of the range of possible revision options for the N categories, including the pros and cons of counting lymph nodes, lymph node stations, or lymph node zones, also provides transparency to the process, explaining why certain options may be discarded, others deferred for future consideration. Finally, we provide a preliminary discussion of the future directions that the N-Descriptors Subcommittee might consider for the 10th edition and beyond.

Published
2023
Full Text
View/download PDF

21. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Author

Van Schil, Paul E., Asamura, Hisao, Nishimura, Katherine K., Rami-Porta, Ramon, Kim, Young Tae, Bertoglio, Pietro, Cangir, Ayten K., Donington, Jessica, Fang, Wentao, Giroux D, Dorothy J., Lievens, Yolande, Liu, Hui, Lyons, Gustavo, Sakai, Shuji, Travis, William D., Ugalde, Paula, Jeffrey Yang, Chi-Fu, Yotsukura, Masaya, and Detterbeck, Frank

Abstract

An international database was created by the International Association for the Study of Lung Cancer (IASLC) to inform the 9thedition of the Tumor – Node – Metastasis (TNM) classification of lung cancer. The present analyses concern its T component.

Published
2023
Full Text
View/download PDF

22. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer

Author

Huang, James, Osarogiagbon, Raymond U., Giroux, Dorothy J., Nishimura, Katherine K., Bille, Andrea, Cardillo, Giuseppe, Detterbeck, Frank, Kernstine, Kemp, Kim, Hong Kwan, Lievens, Yolande, Lim, Eric, Marom, Edith, Prosch, Helmut, Putora, Paul Martin, Rami-Porta, Ramon, Rice, David, Rocco, Gaetano, Rusch, Valerie W., Opitz, Isabelle, Vasquez, Francisco Suarez, Van Schil, Paul, Jeffrey Yang, Chi-Fu, and Asamura, Hisao

Abstract

The accurate assessment of nodal (N) status is crucial to the management and prognostication of non-metastatic non-small cell lung cancer. We sought to determine whether the current N descriptors should be maintained or revised for the upcoming 9thedition of the international Tumor Node Metastasis (TNM) lung cancer staging system.

Published
2023
Full Text
View/download PDF

23. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Author

Raemaekers, John M M, André, Marc P E, Federico, Massimo, Girinsky, Theodore, Oumedaly, Reman, Brusamolino, Ercole, Brice, Pauline, Fermé, Christophe, van der Maazen, Richard, Gotti, Manuel, Bouabdallah, Reda, Sebban, Catherine J, Lievens, Yolande, Re, Allessandro, Stamatoullas, Aspasia, Morschhauser, Frank, Lugtenburg, Pieternella J, Abruzzese, Elisabetta, Olivier, Pierre, and Casasnovas, Rene-Olivier

Published
2014
Full Text
View/download PDF

24. Omitting Radiotherapy in Early Positron Emission Tomography--Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial.

Author

Raemaekers, John M. M., André, Marc P. E., Federico, Massimo, Girinsky, Theodore, Oumedaly, Reman, Brusamolino, Ercole, Brice, Pauline, Fermé, Christophe, van der Maazen, Richard, Gotti, Manuel, Bouabdallah, Reda, Sebban, Catherine J., Lievens, Yolande, Re, Allessandro, Stamatoullas, Aspasia, Morschhauser, Frank, Lugtenburg, Pieternella J., Abruzzese, Elisabetta, Olivier, Pierre, and Casasnovas, Rene-Olivier

Published
2014
Full Text
View/download PDF

25. Health Economic Controversy and Cost-Effectiveness of Proton Therapy.

Author

Lievens, Yolande and Pijls-Johannesma, Madelon

Abstract

Owing to increasing healthcare costs, there is a need to examine whether the benefits of new technologies are worth the extra cost. In proton therapy, where the evidence in favor is limited, it is heavily debated whether the expected benefit justifies the higher capital and operating costs. The aim of this article was to explore the existing methodologies of economic evaluations (EEs) of particle therapy and recommend an approach for future data collection and analysis. We reviewed the published literature on health economics of proton therapy using accepted guidelines on performing EE. Different cost strategies were assessed and comparisons with other treatment modalities were made in terms of cost–effectiveness. Potential bias in the existing studies was identified and new methodologies proposed. The principal cause of bias in EEs of proton therapy is the lack of valid data on effects as well as costs. The introduction of proton therapy may be seriously hampered by the lack of outcome and cost data and the situation is likely to continue not only in terms of justifying the capital investment but also covering the operational costs. We identified an urgent need to collect appropriate data to allow for reimbursement of such novel technology. In the absence of level 1 evidence, well-performed modeling studies taking into account the available cost and outcome parameters, including the current uncertainties, can help to address the problem of limited outcome and health economic data. The approach of coverage with evidence development, in which evidence is collected in an ongoing manner in population-based registries along with dedicated financing, may allow technological advances with limited initial evidence of benefit and value, such as protons, to become available to patients in an early phase of their technology life cycle. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

26. Hypofractionated breast radiotherapy: Financial and economic consequences.

Author

Lievens, Yolande

Subjects
BREAST cancer treatment, CANCER radiotherapy, COST effectiveness, CANCER treatment, MEDICAL care costs, HEALTH outcome assessment, CANCER, ECONOMICS
Abstract

Abstract: A large amount of clinical evidence has recently accumulated supporting the efficacy and safety of hypofractionated radiotherapy for post-operative breast cancer. These schedules, typically delivering a lower total dose in fewer, but larger than 2 Gy fractions, are more convenient for the patients by limiting the number of treatment attendances. Moreover, the reduced resource use in terms of personnel and machine time is advantageous for radiotherapy departments and translates into lower treatment costs. In order to formally validate this therapeutic approach from a societal perspective, however, cost-effectiveness evaluations weighing long-term outcome against the societal costs incurred until many years after treatment are needed. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

27. Radiotherapy cost-calculation and its impact on capacity planning

Author

Lievens, Yolande and Slotman, Berend Jan

Abstract

The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are discussed in this review. Furthermore, the calculation of radiotherapy costs from an institutional perspective using activity-based costing and on capacity planning in radiotherapy – at the departmental as well as at the national level – by integrating cost, epidemiological and scientifico-technological data are focused on.

Published
2003
Full Text
View/download PDF

28. Brachytherapy with Iridium–192 for Bladder Cancer

Author

van Poppel, Hein, Lievens, Yolande, van Limbergen, Eric, and Baert, Luc

Abstract

Objective:Patients with invasive bladder cancer often need radical cystectomy with its implications on quality of life. Bladder preservation combining surgery and radiotherapy could maintain quality of life without compromising tumor control.Study Design:Twenty–eight selected patients with different stages of invasive bladder cancer were treated with preoperative external beam radiotherapy in a dosage depending on the tumor stage. Subsequently they underwent surgical exploration with or without partial cystectomy and insertion of source carrier tubes for afterloading with iridium–192. A close follow–up consisted of 3–monthly urine cytology, cystoscopy and yearly CT scan.Results:Sixteen patients (57%) are alive with no evidence of disease. Five patients (18%) have died of non–cancer–related causes without evidence of recurrent tumor. Tumor progression was seen in 7 patients (25%).Conclusions:Interstitial radiation can result in long–term complete remission in patients with small solitary invasive bladder tumors. The afterloading technique is safe and effective. The selection of patients is the most relevant key to success.

Published
2000
Full Text
View/download PDF

29. Phase III randomized trial of Prophylactic Cranial Irradiation with or without Hippocampus Avoidance in SCLC (NCT01780675)

Author

Belderbos, Jose, De Ruysscher, Dirk, De Jaeger, Katrien, Koppe, Friederike, Lambrecht, Maarten, Lievens, Yolande, Dieleman, Edith, Jaspers, Jaap, Van Meerbeeck, Jan, Ubbels, Fred, Kwint, Magriet, Kuenen, Marianne, Deprez, Sabine, De Ruiter, Michiel, Boogerd, Willem, Sikorska, Karolina, Van Tinteren, Harm, and Schagen, Sanne B.

Abstract

To compare neurocognitive functioning in Small Cell Lung Cancer patients(SCLC) who received prophylactic cranial irradiation(PCI) with or without hippocampus avoidance (HA).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results